

12/10/01
J1131 U.S. PTO

UTILITY PATENT

APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: V-258.00

Page 1 of 2

Title: Method of Production of Purified Hepatitis A Virus Particles
and Vaccine Preparation

Express Mail Label No.: (n/a)

APPLICATION ELEMENTS

INVENTORS: Christa Tauer
Heidi Meyer
Artur Mitterer
Noel Barrett

ADDRESS TO: Assistant Commissioner for Patents

Box Patent Application
Washington, D.C. 2023110/006205
12747891

1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)	10. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449	<input type="checkbox"/> Copies of IDS Citations
2. <input checked="" type="checkbox"/> Specification [Total Pages 45]	11. <input type="checkbox"/> Preliminary Amendment	
3. <input checked="" type="checkbox"/> Drawing(s) (35 USC §113) [Total Pages (Fig. 1-4) 3]	12. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503)	
4. <input type="checkbox"/> Signed Declaration [Total Pages]	13. <input type="checkbox"/> Small Entity Statement(s)	
a. <input type="checkbox"/> Newly executed (original or copy)	14. <input type="checkbox"/> Certified Copy of Priority Documents (s)	
b. <input type="checkbox"/> Copy from a prior application (37 CFR §1.63(d))	15a. <input type="checkbox"/> Cancel in the application original claims _____ before calculating the filing fee	
(Note Box 5 below)		
i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u>	Signed statement attached deleting invento named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)	
5. <input type="checkbox"/> Incorporation By Reference (useable if Box 4b is checked.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	15b. <input type="checkbox"/> Amend the specification by inserting before the first line the sentence: —This is a _____ Continuation, _____ Divisional, _____ Continuation-in-part, of application _____, filed _____	
6. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission	15c. <input type="checkbox"/> I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was signed. I hereby verify that the papers are a true copy of the latest signed prior application number _____, filed _____ aAnd further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 101 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any Patent issuing thereon.	
a. <input type="checkbox"/> Computer Readable Copy	15d. <input type="checkbox"/> Other: _____	
b. <input type="checkbox"/> Paper Copy (identical to computer copy)	15e. <input type="checkbox"/> Other _____	
c. <input type="checkbox"/> Statement Verifying identify of above copies		
7. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))		
8. <input type="checkbox"/> 37 CFR §3.73(b) Statement	<input type="checkbox"/> Power of Attorney	
9. <input type="checkbox"/> English Translation Document		
16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:		
<input type="checkbox"/> Continuation	<input type="checkbox"/> Divisional	<input type="checkbox"/> Continuation-in-part (CIP) of prior application No.: _____

UTILITY PATENT
APPLICATION TRANSMITTAL
(Under 37 C.F.R. §1.53(b))

Docket No.: V-258.00

Page 2 of 2

Title: Method of Production of Purified Hepatitis A Virus Particles
and Vaccine Preparation
Express Mail Label No.: (n/a)

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	51-20 =	31	X \$ 18 =	\$558.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	11-3 =	8	X \$ 84 =	\$672.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ 280 =	\$ 0
				BASIC FEE (37 CFR §1.16(a))	\$740.00
				TOTAL =	\$1970.00

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 02 -1437 (Docket V-258.00).
(For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. Fees required under 37 CFR §1.16
- b. Fees required under 37 CFR §1.17
- c. Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	C. Joseph Faraci, Reg. No. 32,350
SIGNATURE	
DATE	December 6, 2001

CORRESPONDENCE ADDRESS

Baxter Healthcare Corporation
P.O. Box 15210
Irvine, California 92614
Telephone: (949) 250-6827 Fax: (949) 474-6330

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail, Label No. _____ in an envelope addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 on _____.

By: _____